What is PURE Bioscience?
PURE Bioscience is dedicated to the development and commercialization of proprietary antimicrobial solutions, primarily targeting the food safety sector. The company's core technology platform is built upon patented, stabilized ionic silver, with its initial product line featuring Silver Dihydrogen Citrate (SDC). SDC is a broad-spectrum, non-toxic antimicrobial agent that demonstrates superior efficacy, reduced toxicity, and a lower risk of bacterial resistance compared to existing market alternatives. This platform technology is designed to address critical health and environmental challenges related to pathogen and hygienic control.
How much funding has PURE Bioscience raised?
PURE Bioscience has raised a total of $10.2M across 1 funding round:
Stock Offering
$10.2M
Stock Issuance/Offering (2008): $10.2M, investors not publicly disclosed
What's next for PURE Bioscience?
The recent major strategic investment in PURE Bioscience, alongside its substantial total funding of $10.2M, positions the company for accelerated growth and market penetration. This capital infusion is expected to fuel further research and development, expand manufacturing capabilities, and enhance sales and marketing efforts. PURE Bioscience's focus on SDC technology, a distinguished antimicrobial agent, suggests a strategic push to capture a larger share of the food safety and hygienic control markets, potentially leading to new product applications and broader industry adoption.
See full PURE Bioscience company page
